Transcription factors of the nuclear factor of activated T cell (NFAT) family are essential for antigen-specific T cell activation and differentiation. Their cooperative DNA binding with other transcription factors, such as AP1 proteins (FOS, JUN, and JUNB), FOXP3, IRFs, and EGR1, dictates the gene regulatory action of NFATs. To identify as yet unknown interaction partners of NFAT, we purified biotin-tagged NFATc1/␣A, NFATc1/ ␤C, and NFATc2/C protein complexes and analyzed their components by stable isotope labeling by amino acids in cell culturebased mass spectrometry. We revealed more than 170 NFATassociated proteins, half of which are involved in transcriptional regulation. Among them are many hitherto unknown interaction partners of NFATc1 and NFATc2 in T cells, such as Raptor, CHEK1, CREB1, RUNX1, SATB1, Ikaros, and Helios. The association of NFATc2 with several other transcription factors is DNA-dependent, indicating cooperative DNA binding. Moreover, our computational analysis discovered that binding motifs for RUNX and CREB1 are found preferentially in the direct vicinity of NFAT-binding motifs and in a distinct orientation to them. Furthermore, we provide evidence that mTOR and CHEK1 kinase activity influence NFAT's transcriptional potency. Finally, our dataset of NFAT-associated proteins provides a good basis to further study NFAT's diverse functions and how these are modulated due to the interplay of multiple interaction partners.
Transcription factors of the nuclear factor of activated T cell (NFAT) family are essential for antigen-specific T cell activation and differentiation. Their cooperative DNA binding with other transcription factors, such as AP1 proteins (FOS, JUN, and JUNB), FOXP3, IRFs, and EGR1, dictates the gene regulatory action of NFATs. To identify as yet unknown interaction partners of NFAT, we purified biotin-tagged NFATc1/␣A, NFATc1/ ␤C, and NFATc2/C protein complexes and analyzed their components by stable isotope labeling by amino acids in cell culturebased mass spectrometry. We revealed more than 170 NFATassociated proteins, half of which are involved in transcriptional regulation. Among them are many hitherto unknown interaction partners of NFATc1 and NFATc2 in T cells, such as Raptor, CHEK1, CREB1, RUNX1, SATB1, Ikaros, and Helios. The association of NFATc2 with several other transcription factors is DNA-dependent, indicating cooperative DNA binding. Moreover, our computational analysis discovered that binding motifs for RUNX and CREB1 are found preferentially in the direct vicinity of NFAT-binding motifs and in a distinct orientation to them. Furthermore, we provide evidence that mTOR and CHEK1 kinase activity influence NFAT's transcriptional potency. Finally, our dataset of NFAT-associated proteins provides a good basis to further study NFAT's diverse functions and how these are modulated due to the interplay of multiple interaction partners.
The family of NFAT 2 transcription factors consists of five proteins, namely NFATc1 (also known as NFAT2 and NFATc), NFATc2 (NFAT1 and NFATp), NFATc3 (NFAT4), NFATc4 (NFAT3), and NFATc5 (1) (2) (3) (4) (5) . Of these, only NFATc1, NFATc2, and NFATc3 are expressed in lymphocytes. All NFAT proteins consist of an N-terminal NFAT homology region, a highly conserved Rel homology region, and a C-terminal domain (6) . Most NFAT family members can be alternatively spliced to produce various isoforms with different N-and C-terminal domains (6 -8) . However, the importance of different NFAT isoforms is not yet completely understood.
NFAT proteins play a vital role in the course of T helper cell activation, differentiation, and effector function. Although KO of an individual NFAT isoform in T cells leads to rather mild effects, T cells deficient for NFATc1 and NFATc2 completely fail to produce T helper cell effector cytokines, such as the interleukins IL-2 and IL-4 or interferon-␥ (IFN␥) (9 -11) . Thus, NFAT proteins in general are indispensable for the proper function of T helper cells. Hence, inhibition of NFAT activation by cyclosporine A or tacrolimus is highly immunosuppressive and is applied to prevent transplant rejection and to treat various autoimmune diseases (12, 13) .
In a resting state, all NFAT proteins are highly phosphorylated and retained in the cytoplasm. Following T cell receptor (TCR) stimulation, dephosphorylation by calcium-activated calcineurin induces a conformational change of NFAT that exposes one or more nuclear localization sequences (14 -16) . This allows the NFAT protein to enter the nucleus and to activate transcription. Inhibition of calcineurin by cyclosporine A completely prevents NFAT activation, thereby inhibiting T cell activation (1, 17) . Once in the nucleus, NFAT can be re-phosphorylated by diverse kinases (18 -23) , which leads to NFAT inactivation and relocation to the cytoplasm (23) . Additionally, NFAT localization and activation are affected by other mechanisms, including sumoylation, ribosylation, and binding to repressors (14-3-3 proteins and IRF2BP2) or activators (p300 and MEF2D) of NFAT activity (23) (24) (25) (26) (27) (28) .
NFAT readily interacts with other transcription factors (TFs). These interactions strongly influence the locus and the outcome of NFAT binding. By binding to the IL-2 promoter, NFAT in a complex with AP1 promotes IL-2 expression, whereas a complex of NFAT and FOXP3 represses IL-2 expression (15, 29 -31) . In the absence of both interaction partners, NFAT binding to this locus is not detectable (32) . In line with this, NFAT promotes T cell anergy rather than T cell activation in the absence of AP1 activation or if the interaction of NFAT-AP1 is inhibited (32) (33) (34) (35) .
Additionally, NFAT is known to regulate the transcription of many proteins in concert with other transcription factors, such as STAT4 and RUNX1 (36, 37) . So far, however, no direct interaction of these transcription factors with NFAT has been reported. Thus, it remains unclear whether such co-regulation appears in an independent manner, as a hierarchic sequence of events, or whether direct interaction of the transcription factors contributes to these processes.
A recent mass spectrometry (MS)-based study on the interactome of FOXP3 in regulatory T cells revealed that this transcription factor is involved in a large network of protein-protein interactions (38) . This study provided evidence for more than 300 (direct and indirect) interaction partners of FOXP3, including NFATc2 (38) . A similar approach on RelA in HEK293 cells revealed more than 50 high-confident interaction partners of this NFB transcription factor family member (39) .
Despite the pivotal role of NFAT in T cell effector function and differentiation, no such comprehensive study of NFAT interactions has been described. Hence, we studied proteinprotein interaction of three different NFAT isoforms (NFATc1/␣A, NFATc1/␤C, and NFATc2/C) in Jurkat T cells by an unbiased, MS-based approach. Thereby, we identified more than 170 NFAT-associated proteins, including both DNA-dependent and -independent associations. Our analyses suggest that NFAT proteins can cooperatively bind with RUNX1 and CREB1 proteins to cognate DNA recognition motifs. Furthermore, we provide evidence that the activity of the NFAT-associated kinases mTOR and CHEK1 has an impact on NFAT's potential to activate transcription.
Results

Generation of Jurkat Cell Lines That Express Biotin-tagged
NFAT Proteins-To isolate NFAT-containing protein complexes, we generated epitope-tagged versions of human NFATc1/␣A, NFATc1/␤C, and NFATc2/C. The two splice variants of NFATc1 differ in their C and N termini and are known to possess some non-redundant functions and an individual expression pattern (Fig. 1B) (8, 40, 41) . The employed tag contained a biotinylation site for the Escherichia coli biotin ligase BirA and a TEV-cleavage site (BT tag). Thereby, the tag allows for protein isolation via streptavidin-coupled agarose beads and a mild and specific elution of the caught protein complexes via cleavage by TEV protease (Fig. 1A) . All used BTtagged NFAT variants were found to drive luciferase expression from an NFAT-reporter plasmid to a similar extent as the wildtype NFAT variants (data not shown).
We used bicistronic retroviruses (NFAT-GFP and BirAmCherry) to stably introduce one of the NFAT variants and the biotin ligase into the Jurkat human T cell line. Transduced GFP ϩ /mCherry ϩ double-positive cells were sorted by FACS and NFAT overexpression, and biotinylation was checked by Western blotting (Fig. 1C) . The level of overexpression was higher for NFATc1/␤C and NFATc2/C than for NFATc1/␣A (Fig. 1, D and E) . We obtained control cells that overexpressed BirA alone, a combination of BirA and non-tagged (i.e. wild type) NFAT proteins, BirA and BT-GFP or BirA and BT-histone H4, by an analogous strategy. We confirmed the potential of our NFAT-BT fusion proteins to study NFAT protein interactions by the specific co-purification of the known NFAT protein interactors p300, c-JUN, JUNB, and c-FOS along with the captured NFATc2-BT (data not shown) (28, 31, 42) .
Identification of NFAT-associated Proteins by SILAC Mass Spectrometry-To identify hitherto unknown interaction partners of NFAT proteins by MS, we differentially labeled pairs of NFAT-BT expressing bait cells and corresponding control cells with stable isotopes (SILAC). Subsequently, we isolated protein complexes from stimulated bait and control and analyzed the eluates by MS.
Overall, between 500 and 800 proteins were identified and quantified via at least two unique peptides in individual runs ( Fig. 1F and (supplemental Table 1) ). Most proteins (82-98%) that were identified in one run of one experiment were also identified in a second run (Fig. 1G) . A third run for NFATc1/ ␤C, which originated from a separate sample preparation, showed a decreased but still substantial overlap with the two other runs (58 -78%). For further analysis, we regarded only those proteins that were identified in at least two individual MS runs.
As expected, the respective NFAT bait was highly enriched in each experiment (Fig. 1F) . Although a majority of the further identified proteins were not, or only slightly, enriched compared with the paired control experiments, several proteins were identified in CoIPs with NFAT proteins with an enrichment factor above 3 (Fig. 1F) . In detail, 9 proteins were enriched together with NFATc1/␣A, 63 proteins with NFATc1/␤C, and 160 proteins with NFATc2/C (Fig. 1F) . Importantly, this enrichment can be a result of either a direct interaction with the bait protein or of indirect interactions mediated by other proteins.
Interestingly, there was a substantial overlap of associated proteins of the various NFAT variants. 8 of the 9 proteins (88%) that were enriched along with the short ␣A variant of NFATc1 were also enriched along with the long ␤C variant. Additionally, 45 of the 63 proteins (71%) that were associated with NFATc1/␤C were also associated with NFATc2/C (Fig. 1H) . The list of enriched proteins contained several known NFAT interaction partners, such as the NFAT kinases casein kinase-1 and GSK3␤, CREB1 (enriched together with all three isoforms), p300, JunB (NFATc1/␤C and NFATc2/C), c-JUN, c-FOS, and EGR-1 (NFATc2/C, see Table 1 ).
All control cells that were used in the MS experiments expressed the biotin ligase BirA to exclude that the biotinylation of other proteins than the bait proteins resulted in arbitrary enrichment of these proteins. Furthermore, the control cells overexpressed non-tagged, i.e. wild type, forms of the corresponding bait proteins (NFATc2/C and NFATc1/␤C) to exclude that differential protein expression caused by the overexpressed NFAT introduced an artificial bias into the experiments. However, for technical reasons, control cells for the NFATc1/␣A experiments only expressed the BirA ligase. Altogether, because our experiment confirmed already known NFAT interactions, we were confident that other enriched proteins also constitute direct or indirect interaction partners of the particular NFAT isoforms.
Ikaros and NFATc2 Interact in T Helper Cells after TCR
Stimulation-To further validate the results from the MS experiments, we handpicked a selection of the newly identified association partners of NFATc2/C for CoIP immunoblotting ( Fig. 2A) . To this end, NFATc2/C-containing protein complexes were stripped from the streptavidin beads by boiling in SDS sample buffer after isolation steps were performed as for the MS analysis.
The proteins Raptor, SATB1, WDR48, Ikaros, Helios, SCAI, RUNX1, and CHEK1 were enriched in the eluates from cells that overexpress biotinylated NFATc2/C but not from control cells overexpressing the biotin ligase BirA and wild-type NFATc2/C. Thus, we were able to confirm the association of NFATc2 with these proteins, which were revealed by the MS experiments.
To test whether NFATc2 and Ikaros also associate in primary human T helper cells, we performed proximity ligation assays (PLA) using antibodies against these proteins. In this assay, the recognition of two proximate proteins by differently labeled antibodies results in signals that can be detected by fluorescence microscopy (43).
Although untreated freshly isolated CD4-positive T cells showed only few PLA signals per cell (median ϭ 1, Fig. 2 , B and C), the median amount of signals per cell increased to 16 when cells were stimulated with PMA and ionomycin. The addition of 50 nM CsA reduced the amount of signals per cell to the level of unstimulated cells. Cells stimulated with anti-CD3/CD28 beads also showed an augmented signals per cell ratio (median ϭ 9). Although there was a lower frequency of cells with five and more signals per cell compared with PMA/ionomycin-stimulated cells (62% versus 92%), the median signal count of these subsets did not differ significantly (data not shown). When one of the antibodies was exchanged for an isotypematched control antibody, again only few signals per cell were detectable in PMA/ionomycin-treated cells (Fig. 2B, lower panel) . To further test the specificity of the PLA signals, we generated Jurkat cells that were deficient for either Ikaros or NFATc2 by the help of CRISPR/Cas9 technology ( Fig. 2D) (44) . Using the same antibodies as before, we detected a median of six PLA signals per cell in stimulated wild-type cells. In contrast, a median of only 0 or 1 signals per cell was detected in stimulated cells deficient for NFAT or Ikaros, respectively (Fig. 2E ). This confirmed that the observed PLA signals are strongly dependent on the presence of both NFATc2 and Ikaros protein, whereas unspecific binding events do not account for the highly augmented signals in stimulated cells. Taken together, our PLA data indicate that NFATc2 and Ikaros interact in stimulated but not in unstimulated human T helper cells.
NFAT Associations Subdivide into DNA-dependent and DNA-independent-Because we successfully validated individual NFATc2 protein associations by Western blotting and PLA, we took a closer look at the complete lists of enriched proteins. GO-term analyses revealed that roughly half of the enriched proteins are capable of DNA binding, and a quarter is designated as transcription factors (supplemental Table 3 ). This points toward the possibility that individual NFAT associations take place at the DNA or may be strengthened by DNA binding.
To test whether the observed NFAT associations are in general dependent on DNA binding, we performed CoIPs in the presence or absence of the DNA-intercalating agent GelRed. This agent strains the DNA, thereby reducing protein-DNA interaction (45) . As a result, DNA-mediated protein-protein interactions should be diminished in the presence of the agent (illustrated in Fig. 3A ).
As shown in Fig. 3 , B and C, the association of NFATc2 with the transcription factors RUNX1, c-FOS, c-JUN, Ikaros, Helios, and SATB1 is at least in part mediated by binding to DNA, as the presence of GelRed reduced the co-purification with NFATc2. In contrast, the association between NFATc2 and CREB1 was not reduced, pointing toward an association even in the absence of DNA binding. As expected, SCAI and the kinases GSK3␤ and CHEK1 associate with NFATc2 independent of DNA binding (Fig. 3, B and C) . Notably, all tested proteins were co-purified with NFATc2-BT but not with a BT-tagged GFP.
To exclude that some of the observed NFAT associations occur independently of protein-protein interactions and are solely mediated by DNA linkage (Fig. 3A) , we performed CoIP experiments with or without prior DNase I digestion. Success of the DNA digestion was checked by agarose gel analysis before and after digestion (Fig. 3D ). Because DNase I digests DNA that is not protected by proteins, associations that are mediated solely by DNA linkage should be abrogated (Fig. 3A ). Again, all tested proteins were co-purified with NFATc2-BT but not with the BT-tagged GFP (Fig. 3, E and F) . Importantly, none of the observed associations were substantially reduced by DNase I treatment. This demonstrates that, at least for the tested proteins, the observed associations with NFATc2 do not solely rely on DNA linkage. Thus, our results suggest that NFAT association with c-FOS, c-JUN, Ikaros, Helios, and SATB1 is strengthened by DNA binding, whereas the binding to CREB1, CHEK1, SCAI, and GSK3␤ is DNA-independent.
Binding Motifs for RUNX, Ets, AP1, and NFB Factors Are Enriched in NFAT ChIP-Seq Peaks-Next, we studied whether the DNA-binding motifs for NFAT-associated transcription factors are (a) enriched in regions of NFAT binding and (b) are preferentially near the NFAT recognition motifs. To test this, we took advantage of a recently published ChIP-Seq dataset that identified over 24,000 NFATc2 binding regions in primary murine CD8 ϩ T lymphocytes 1 h after stimulation (32) . Using the oPOSSUM software platform, known transcription factorbinding motifs were mapped within these regions (46) . First, we examined which transcription factor-binding motifs were enriched in this collection of regions of confirmed NFATc2 binding (Fig. 4, x axis) . Binding motifs that were enriched in these regions (compared with a control dataset) appear further right in the figure. As expected, NFAT-binding motifs were highly enriched in the dataset. Additionally, we found a strong enrichment of motifs for AP1-like sites (JUN, JUND, JUNB, and FOS) as well as RUNX-binding motifs (RUNX and CBFB). To a lesser extent, motifs for Ets-like transcription factors (ETV6, ELK1, ELK4, and ELF5) and B sites were over-represented. Thus, binding motifs for some of the NFAT-associated transcription factors (AP1 proteins, ETV6, and RUNX1) are found enriched in regions of NFAT binding, albeit not for all.
Binding Motifs for RUNX1, AP1, and CREB Proteins Are Enriched Close to Those for NFAT-Next, we performed an anchored combination site analysis to investigate the occurrence of TF-binding motifs in spatial relation to NFAT-binding motifs. Therein, we compared the relative abundance of the binding motifs within a window of 20 and 100 bp around NFAT-binding motifs, respectively (Fig. 4, y axis) . A positive score indicates that a specific TF-binding motif is more enriched within the 20-bp window. Binding motifs with a higher score are depicted further up in Fig. 4 and are found more likely in close proximity to NFAT-binding motifs.
In line with the original report of this dataset (32), we found that AP1 and RUNX/CBFB binding motifs were located near the NFAT motifs. Additionally, we observed a strong enrichment of binding sites for MAFG, NFB, nuclear receptors, EGR1, and PAX proteins in the vicinity of NFAT motifs. A weaker but still significant enrichment was found for CRE (CREB1 and ATF7), helix-like transcription factor and several other transcription factor-binding motifs (Fig. 4, y axis) . Together with the observation that NFAT proteins can associate with MAFG, RUNX1, CREB1, ATF7, and AP1 proteins, our findings suggest that NFAT and these proteins can bind conjointly to nearby DNA sequences.
Co-occurrence of Pairs of Transcription Factor-binding Sites-To identify TFs that might cooperate with NFAT in DNA binding, we used our analytic tool CobindR to identify pairs of recognition motifs for NFAT and other transcription factors in the aforementioned dataset (47, 48) . The distance (in base pairs) between those binding sites and the location of the second motif (upstream (ϩ) or downstream (Ϫ) of the NFAT motif) were determined. Subsequently, pairs that occurred preferentially in defined distance and location to present NFAT motifs were detected.
NFAT-AP1 was by far the most significant binding motif pair (Fig. 5A, left panel) , with the AP1 motif found directly downstream of an NFAT motif most frequently. This composite NFAT-AP1 motif was found more than 900 times in the dataset.
For comparison, we also applied this analysis to a second ChIP-Seq dataset from the same report, which is composed of 11,000 binding regions of an engineered NFATc2 variant that cannot bind to AP1 (Fig. 5A, right panel) . As one would expect, the relative amount of composite NFAT-AP1 sites was significantly reduced (ϳ50%) compared with the first dataset. Nevertheless, we observed a still substantial amount of NFAT-AP1 composite sequences in this second data set. This suggests that NFAT binds to a subset of these sites even in the absence of the NFAT-AP1 interaction.
These expected observations (32, 49) encouraged us to take a closer look at other pairs. A further binding motif that was found preferentially in a defined distance to NFAT is the CRE motif (Fig. 5B, left) . It constitutes the consensus-binding site of CREB1 and some transcription factors of the ATF family, but it can also be bound by AP1 (50) . The CRE consensus sequence (TGACGTCA) is similar to the AP1 consensus sequence (TGA(C/G)TCA) with the exception of an additional central nucleotide. Similar to the AP1 motif, the CRE motif is found preferentially 1 bp downstream of the NFAT motif. Thus, the resulting NFAT-CRE motif is very similar to the previously identified NFAT-AP1 motif with regard to sequence, distance, and orientation. The motif was found ϳ250 times within the dataset.
Interestingly, the NFAT-CRE motif was not enriched in the ChIP-Seq regions bound by the AP1-binding deficient NFAT (Fig. 5B, right) . This indicates that either the NFAT-CRE motif is bound preferentially by an NFAT-AP1 complex or that the introduced mutations of the NFAT variant also interfere with the NFAT-CREB1 interaction.
Additionally, our analysis revealed a highly significant enrichment of RUNX-binding sites directly upstream of NFAT-binding motifs in both employed datasets (Fig. 5C) . Interestingly, this composite RUNX-NFAT motif was even more highly enriched in the ChIP-Seq dataset of the AP1-binding deficient NFAT.
In contrast to the AP1 and the CRE motif, the RUNX consensus motif (as the NFAT motif) is not palindromic. Interest- ingly, only the forward oriented RUNX motif is found enriched at position Ϫ1 in relation to the forward oriented NFAT-binding motifs, whereas for the reverse orientation no distance to NFAT motifs is enriched over background (Fig. 5D) . Thus, when all four possible orientations of the motifs were considered, only the combination of the forward RUNX motif upstream to the forward NFAT motif was enriched. We used the motif pairs of the preferred distance and orientation and generated consensus binding sequences of the postulated NFAT-RUNX, NFAT-CRE, and NFAT-AP1 and pairs, which are depicted in Fig. 5E .
Protein Associations of NFATc1/␣A, NFTAC1/␤C, and NFATc2/C Show a Substantial Overlap-Although many proteins are associated with both NFATc1 and NFATc2 proteins (Fig. 1H ), we were interested to confirm differences in the association patterns. To this end, we purified BT-NFATc1/␣A, NFATc1/␤C-BT, and NFATc2/C-BT in parallel from stimulated cells and compared the abundance of co-purified association partners by immunoblotting (Fig. 6A) . For a negative control, we isolated protein complexes from BT-GFP-, BT-histone-H4-, or BirA-overexpressing cells in parallel.
To compare the enrichment of co-purified proteins with the different bait proteins, we quantified the signals and normalized the signal intensities of the co-purified prey proteins to the signal intensity of the corresponding bait protein. For visualization of the differential association patterns, Fig. 6B shows the relative enrichment of the co-purified proteins over three experiments in relation to their relative enrichment with NFATc2/C as a bait protein, which was set to 1.
Interestingly, we observed that Raptor and p300 were not co-purified with the short variant NFATc1/␣A, but they were with both the long variant NFATc1/␤C and with NFATc2/C to a comparable degree. Higher amounts of WDR48, SATB1, CREB1, c-JUN, c-FOS, and RUNX1 were co-purified with NFATc2/C than with the other NFAT isoforms. On the contrary, NFATc1/␤C was associated with the highest amounts of GSK3␤ and SCAI (Fig. 6) . Helios, Ikaros, and CHEK1 were co-purified with all three variants to a comparable extent.
Protein complexes isolated from BT-GFP-, BT-histone-H4-, or BirA-overexpressing cells served as the negative control. In general, the amounts of protein that co-purified with the different NFAT proteins exceeded those observed in the control experiments. One exception from this was observed for WDR48, which was enriched over control levels only together with NFATc2. In contrast, similar amounts of the proteins Stat1 and LaminB were observed in all bait and control experiments (Fig. 6A) . Thus, although we observed a strong overlap of associated proteins between the different NFAT isoforms, we detected qualitative (p300 and Raptor) and quantitative (e.g. CREB1 and GSK3␤) differences.
CHEK1 and mTOR Affect NFAT Activity-Our data demonstrate that the kinase CHEK1 and the mTOR-interacting protein Raptor can associate with NFATc1 and NFATc2. Because NFAT activity is regulated by phosphorylation, we asked whether the newly identified NFAT-associated kinases might regulate NFAT's transcriptional activity in T cells. Using an NFAT luciferase reporter plasmid, we performed reporter gene assays in Jurkat cells in the presence or absence of the CHEK1 inhibitor Chir124 and the mTOR inhibitor rapamycin (Fig. 7A)  (51, 52) .
Interestingly, rapamycin increased the stimulation-induced luciferase activity by ϳ20%, whereas the CHEK1 inhibitor decreased luciferase activity to ϳ80% of the control cells. Experiments using a second CHEK1 inhibitor (MK-8776) (53) confirmed the results, because this inhibitor significantly reduced NFAT luciferase activity, too (Fig. 7B) . In contrast, the activity of a constitutively expressed luciferase was not significantly reduced by either of the CHEK1 inhibitors (Fig. 7C) . Thus, both CHEK1 and mTOR seem to influence NFAT activity in T cells, albeit in different directions.
Discussion
The activation of NFAT family transcription factors is a hallmark of T cell activation and differentiation, as NFAT proteins are indispensable for the function of T cells and the adaptive immune system as a whole (9, 54) . The interaction of NFAT proteins with other transcription factors (e.g. FOXP3, AP1, or GATA3) strongly influences NFAT DNA-binding sites and target gene activation (30, 31, 55) .
By performing global MS-based interaction analysis, we identified more than 170 proteins as potential interactors of NFATc1 and NFATc2 ( Fig. 1 and Table 1 ). Most of these constitute newly identified partners of NFAT proteins and link NFAT proteins to several other transcription factors, to the SWI/SNF complex, or to the DNA-damage response. Additionally, our analysis confirmed several NFAT interactions that were previously identified by others, such as AP1 proteins, the co-activator p300, 14-3-3 proteins and known NFAT kinases (15, 19, 23, 28, 42) .
We confirmed the association of eight newly identified NFAT partners (e.g. Raptor, CHEK1, RUNX1, and Ikaros) with NFAT proteins by CoIP-immunoblotting (Fig. 6 ). This emphasizes the potential of the affinity purification MS approach to identify previously unanticipated associations. The number of associated proteins is in the range of similar MS-based studies, which analyzed the interactome of the transcription factors FOXP3 and REL-A and yielded 363 and 50 interaction partners, respectively (38, 39) . However, the number of identified associated proteins strongly depends on the experimental design (e.g. choice of cells, tag, level of overexpression, and washing stringency) and data processing (e.g. enrichment factor cutoffs).
Roughly one-half of the enriched proteins have the ability to bind to DNA, as revealed by GO term analyses. Interestingly, one-fourth were designated as transcriptions factors. It is likely that NFAT and several of these transcription factors bind as complexes to DNA recognition sites, because (i) their association is often dependent on DNA binding (Fig. 3) ; (ii) their DNAbinding motifs are found enriched in regions of NFAT binding (Fig. 4) ; and (iii) these motifs preferentially occur in a certain distance and orientation to NFAT recognition motifs (Fig. 5) .
Our data show that many transcription factors, such as Helios, Ikaros, SATB1, and RUNX1, can associate with NFATc1 and NFATc2 in a DNA-dependent manner (Fig. 3B) . This indicates that binding to nearby or overlapping DNA sequences may contribute to the stability of these associations.
This hypothesis is further strengthened by co-localization analyses, which revealed that CRE-, RUNX-, and AP1-binding motifs are highly enriched in direct vicinity to those for NFAT (Fig. 4) . For each of these pairs, we found a preferred distance and orientation of the transcription factor recognition motifs (Fig. 5) .
Together, these observations strongly suggest that these composite sites are bound by transcription factor complexes that rely on protein-protein interactions as well as protein-DNA interactions. The structure of the complexes can dictate the orientation and distance of the individual DNA binding domains and would explain the observed preference for defined composite binding motifs (Fig. 5 ). In line with this, independent binding of two transcription factors to one common regulatory region would most likely not favor one certain distance between the binding motifs, while competitively bound recognition sites would not prefer a distinct orientation of the two binding motifs. Thus, our data suggest that a large subset of these sites can indeed serve as dimeric recognition sites for NFAT and TFs that bind to RUNX, CRE, and AP1 motifs.
It is important to note that the employed algorithm only recognized motifs that exceeded a high threshold of sequence agreement with the consensus sequences of the individual transcription factor recognition motifs. However, transcription factors that bind cooperatively to overlapping DNA sequences are more tolerant to alterations of the recognition motifs and can bind with high affinity to degenerated composite recognition sites that are hardly recognized by each TF individually (49, 56) . Furthermore, the optimal binding motif for a TF heterodimer does not need to be a simple combination of the individual recognition sequences but may differ substantially (57) .
Therefore, we probably underestimated the number of dimeric recognition motifs for pairs of NFAT and other transcription factors. It is likely that this concerns especially those sites that are hardly bound by individual TFs but require corporate binding of both respective transcription factors. Such cooperative binding of transcription factors to composite DNA sequences can function as signal integration and has been described for NFAT together with IRF4, JUN, FOS, FOXP3, CREB1, and NFB (31, 37, 58 -61) .
From the MS data, we cannot exclude that some of the NFAT-associated proteins were enriched solely because they bound to co-purified DNA molecules. By performing CoIPs after DNase I digest, we ruled out this caveat for the tested subset of proteins (Fig. 3C) . Furthermore, we did not observe any co-purification of the tested proteins when we used histone H4 as bait protein, which should also co-purify DNA and DNAbinding proteins (Fig. 6) . Hence, co-purification by DNA binding does not account for the tested associations of other proteins with NFAT. However, this has yet to be proven in future experiments for the remaining proteins from the MS data set.
A similar concern is that enriched proteins may bind to the tag rather than to the NFAT moiety of the fusion protein.
For the tested proteins, we observed co-purification with BTtagged NFAT proteins but not with BT-tagged GFP or histone H4 (Figs. 3 and 6) . Again, similar proof for other proteins from the dataset has to be furnished. The transcriptional activity of NFAT proteins is mainly regulated by their phosphorylation status (14) . Although kinases such as DYRK, GSK3␤, JNK, p38, PKA, and CK1 inactivate NFAT, phosphorylation by PIM1, Cot, and VRK2 further activate NFAT's activity (18 -22, 62-64) .
Here we provide evidence that the kinases mTOR and CHEK1 also contribute to the dynamic regulation of NFAT's activity in T cells. First, both CHEK1 and mTOR (via Raptor) associate with NFATc1 and NFATc2 (Fig. 6) . Second, inhibition of mTOR increased and inhibition of CHEK1 decreased the activity of an NFAT-Luciferase reporter after T cell stimulation (Fig. 7) . However, there is a need for further functional studies to determine whether NFAT proteins are direct targets of these kinases.
A link between mTOR and NFAT activity in T cells has already been suggested by other studies (65, 66) . mTOR can phosphorylate NFATc4 on two serine residues, thereby maintaining NFATc4 in the cytosol (65) . Interestingly, one of these serine residues is present in all NFAT isoforms. In line with this, a recent report demonstrated that rapamycin treatment of primary murine T cells leads to an increase of nuclear NFATc1 following TCR/co-receptor stimulation (66) . However, further work is needed to clarify whether the known effects of mTOR on T cell proliferation and differentiation may in part be mediated via the regulation of NFAT activity (67, 68) . The activation by CHEK1 links NFAT activity to cell cycle regulation (69) . In the light of NFAT playing a well known role as an oncogene in several tumors, the interdependence between cell cycle kinases and NFAT appears interesting (70, 71) .
In most cases, protein interactions have functional consequences, and the discovery of hitherto known NFAT interactions followed their prediction based on functional overlap (15, 60, 61) . In contrast, our MS-based screen for NFAT-associated proteins allowed an unbiased identification of "novel" NFAT partners. Nevertheless, NFAT proteins and several of the newly identified NFAT-associated proteins impact on common cellular programs such as T cell differentiation and proliferation (mTOR, Ikaros) or have common target genes (e.g. RUNX1 and SATB1) (36, 37, 66, 72, 73) .
For example, although it is known that NFAT and RUNX1 co-regulate the expression of several important genes (37, 74 -76) , no direct interaction has been described so far. Here, we observed an association between RUNX1 and NFAT proteins in Jurkat cells, which was supported by DNA (Fig. 3) . Furthermore, RUNX1-binding motifs are enriched in close proximity to NFAT-binding motifs (Fig. 4) . Remarkably, both motifs occur preferably in a certain distance and a distinct orientation to each other (Fig. 5) . Out of four possible orientations that the two motifs could adopt, only one is enriched, underlining that RUNX and NFAT proteins may form a tripartite complex with DNA that involves protein-protein interactions. The dynamic regulation of these complexes will certainly impact the expression of common target genes.
The transcriptional repressor Ikaros associates with NFATc1 and NFATc2 in a DNA-dependent manner (Figs. 2 and 3) , too. Although we did not find Ikaros-binding motifs enriched in regions of NFAT binding from CD8 T cells (Fig. 4) , this does not exclude NFAT and Ikaros interaction in trans. In particular, our PLA data suggest a signal-dependent interaction of Ikaros and NFATc2 in T cells.
To date, we can only speculate on the functional implication of this interaction. One hypothesis is that Ikaros can suppress the expression of activation-related NFAT target genes via the association with NFAT proteins, while not affecting genes necessary for anergy induction. This would be in line with the findings by others and that Ikaros suppresses IL-2 production in anergic T cells (77) and that suppression of effector T cells by regulatory T cells requires NFATc2-dependent up-regulation of Ikaros in the suppressed cells (73) .
In contrast to most other transcription factors, CREB1 associates with NFAT even in the absence of DNA binding (Fig. 3) . Furthermore, the identification of overlapping NFAT-CRE sites in regions of NFAT binding suggests that NFAT-CREB1 complexes may recognize cognate DNA-binding sequences (Fig. 5) . This is further supported by the fact that the two proteins regulate the expression of common target genes, such as those coding for IL-2, IL-4, IL-10, IFN␥, RANKL, and FOXP3 (36, 61, 78 -83) . Thus, cooperative DNA binding of NFAT and CREB1 proteins may play a role in the co-regulation of these and further genes.
Finally, our dataset of NFAT-associated proteins provides a good basis to further study NFAT-based protein-protein interactions. We are confident that a large subset of the 170 proteins will be confirmed as NFAT interaction partners in the future. It will be enlightening to evaluate to what extent protein-protein interaction between NFAT and associated proteins function as points of signal integration and contribute to common regulatory effects. This will help to better understand how NFAT proteins regulate such diverse processes as T cell activation, differentiation, anergy induction, and cancer progression.
Experimental Procedures
Antibodies and Reagents-Specific antibodies against the following antigens were used: CHEK1 (mouse, AM20031AF-N, Acris); CREB1 (rabbit, 48H2), c-FOS (rabbit, 9F6), GSK3␤ (rabbit polyclonal), c-JUN (rabbit, 60A8), JUNB (rabbit, C37F9), Raptor (rabbit, 2280), SCAI (rabbit, 12892, all from New England Biolabs); EP300 (rabbit, C20), Helios (goat, M20), Ikaros (rabbit, H100-x), LAMIN-B (goat, M20), RUNX1 (goat, C19), ACTB (mouse, C4, all from Santa Cruz Biotechnology); NFATc1 (mouse, 7A6), NFATc2 (mouse, NFAT1, for PLA), SATB1 (mouse, 14/SATB1, all from BD Biosciences); WDR48 (rabbit, ab122473, Abcam); and GFP (goat, 600-130-215, coupled to IR DYE700, Rockland). Affinity-purified rabbit polyclonal antibodies raised against the middle protein region (amino acids 202-687) of human NFATc2 were used for the detection of NFATc2 during Western blotting (84) . IR-DYE coupled secondary antibodies from donkey were obtained from LiCOR. IR-DYE700 coupled streptavidin was obtained from Molecular Probes.
Complete protease inhibitor (with or without EDTA) was obtained from Roche Applied Science; JNK inhibitor VII, kenpaullone, PD169-316, and ellagic acid were obtained from Biaffin. Sodium-glycerol-phosphate, sodium orthovanadate, and sodium pyrophosphate, ionomycin, PMA, and the Duolink starter kit (mouse-rabbit, red) were obtained from Sigma.
CHIR-124 was obtained from Selleck Chemicals; rapamycin was from Miltenyi, and CsA was from AWD, Dresden, Germany. MobiTEV protease was obtained from MoBiTec GmbH.
Cells-Jurkat E6 cells were obtained from ATCC and were cultivated in RPMI 1640 medium supplemented with 10% FCS, 100 units/ml penicillin, 100 g/ml streptomycin, and 10 g/ml ␤-mercaptoethanol. HEK293FT were obtained from Invitrogen, and cells were cultured in DMEM supplemented with 10% FCS, 100 units/ml penicillin, and 100 g/ml streptomycin. Jurkat cells and HEK cells were stimulated by addition of PMA (20 ng/ml) and ionomycin (1 g/ml) to the culture medium, which was supplemented with 1 mM CaCl 2 .
For the isolation of primary human CD4 ϩ T cells, peripheral blood mononuclear cells were isolated from healthy donor blood (DRK, Berlin, Germany) using Percoll density gradient, and CD4
ϩ cells were positively selected by CD4 MACS beads (Miltenyi). Primary T cells were stimulated with Dyna T cell activator beads (Life Technologies, Inc.) that were added to the cells in a bead-to-cell ratio of 1:1.
Vectors and Constructs-The retroviral auxiliary plasmids pVSVG and pCPG and the pMSCV-IRES-GFP (pMIG) vector were a kind gift from the research group of Andreas Radbruch, DRFZ, Berlin, Germany. Human NFATC2 protein-coding sequence was amplified from human cDNA. The sequence corresponds to NM_173091.3 with the silent mutation A1723C. Human NFATC1/␣A sequence was subcloned from pREP-NFAT2, which was a gift from Anjana Rao (Addgene plasmid 11788, sequence originates from Northrop et al. (2)), and corresponds to NM_172390.2 with the mutation G1157A (R235Q) and the silent mutation C1980T. Human NFATC1/␤C (NM_172387) and human histone H4 (NM_003540.3, human codon usage optimized) coding sequences were synthesized by GeneScript.
The pMIG vector backbone was prepared for the expression of proteins with an attached tag consisting of a BirA-biotin ligase site and a TEV cleavage site either at the N or C terminus. Sequences of NFATc1/␣A, NFATc1/␤C-BT, and NFATc2/C-BT, histone-H4, and GFP were subcloned into the N-BT, the C-BT, and into the core vector without any tag, respectively. Cells expressing BT-NFATc1/␣A, NFATc1/␤C-BT, and NFATc2/C-BT were used for co-immunoprecipitation studies.
The pBY2982, containing the E. coli biotin ligase birAmCherry fusion protein sequence was a gift from Ralf Baumeister (Addgene plasmid 23220) (85) . The construct was subcloned into the pMSCV vector without GFP. The human EF1␣ promoter was cloned prior to the BirA open reading frame to enhance expression, and the linker sequence between BirA and mCherry was exchanged for the P2A self-cleaving peptide (86) by overlap extension PCR.
The CRISPR/Cas9 vector pSpCas9(BB)-2A-GFP (PX458) was a gift from Feng Zhang (Addgene plasmid 48138) (44) . The CBh promoter was replaced by the hEF1␣ promoter to allow stronger transgene expression in Jurkat cells. Guide RNAs were designed by the help of the CRISPR design web-tool (Massachusetts Institute of Technology) to target early exons expressed by all isoforms of the respective protein. To minimize off-target effects, only gRNAs that possess at least three mismatches to known human DNA sequences were used. Two non-matching guanidine nucleotides were added to the 5Ј end of the guide to further enhance specificity (87) . Another on-line tool was used to identify potential highly active gRNA sequences (88) . The following sequences were used as gRNAs: NFATc2 (ggGCCGCAGAAGTTTCTGAGCG) and Ikaros (ggTCTGGAGTATCGCTTACAGG). The gRNA sequences were synthetized with overhangs and inserted into the vector as described by Ran et al. (44) . The coding sequences of all used vector constructs were confirmed by Sanger sequencing. All plasmids (including sequences) are deposited at Addgene and can be obtained from their website.
Retrovirus Production and Transduction of Jurkat Cells-HEK293 FT cells were transfected by calcium precipitation with the transgene containing pMSCV vector(s) plus retroviral auxiliary plasmids pVSVG and pCGP. Retroviruses were harvested after 24 h, filtered, and supplemented with 20 mM HEPES, pH 7, and Polybrene (8 g/ml). Jurkat cells were resuspended in retroviral supernatant, spun for 90 min at 1000 ϫ g, and incubated for an additional 2 h in the retroviral supernatant. After 7 days, cells were sorted for GFP-and/or mCherryexpressing cells via FACS. 10 6 Jurkat cells were transfected with 2 g of the CRISPR/Cas9 plasmids bearing the target gene-specific gRNA by nucleofection (Lonza Nucleofector IIb, kit V, program X-001). One day post-transfection, transfected cells were sorted for GFP expression by FACS. Single cells were expanded clonally and screened for phenotypic knock-out by Western blotting analysis.
Establishment of Knock-out Cell Lines by CRISPR/CAS9 -
SILAC Labeling of Jurkat Cells-SILAC media were prepared from RPMI 1640 medium without arginine and lysine by addition of 10% dialyzed FCS, 2 mM L-glutamine, 100 units/ml penicillin, 100 g/ml streptomycin, 0.115 mM light or heavy arginine, and 0.275 mM light or heavy lysine, respectively. 2.6 mM light L-proline was added to all media to avoid arginine-to-proline conversion (89) . For SILAC experiments, cells were grown in heavy or light SILAC medium for at least 10 days.
Co-immunoprecipitation-For CoIP of NFAT-containing complexes or control proteins, 2-3⅐10 8 stably transfected Jurkat cells were stimulated for 2 h with PMA/ionomycin. Lysis protocol was adopted from Klenova et al. (90) and was used for all CoIP experiments, including the CoIP-MS experiments. Washed cells were resuspended in hypotonic buffer (25 mM HEPES, 25 mM NaCl, 2 mM EDTA, 0.1% Tween 20) and put on ice for 10 min. The suspension was spun for 1 min at 8000 ϫ g, and the pellet (containing nuclei) was resuspended in high salt buffer (500 mM NaCl, 25 mM HEPES, 2 mM EDTA, 0.5% Tween 20), incubated on ice for 30 min, subjected to ultrasound shearing, and incubated again on ice for 30 min. The nuclear lysates were diluted with 2 volumes of 10 mM HEPES and cleared by centrifugation at 13,000 ϫ g.
For DNase I digest, a further 3 volumes of dilution buffer were added, and the lysate was supplemented with 5 mM MgCl 2 and 1 mM CaCl 2 , and DNase I (2000 units, recombinant, Roche Applied Science) was added. Digest was done on ice for 90 min and abrogated by addition of 10 mM EDTA and 50 mM NaCl. To monitor DNA digestion, DNA was extracted from a portion of the extracts using spin column purification (Macherey Nagel) and separated by electrophoresis on a 1% GelRed-agarose gel. NOVEMBER 11, 2016 • VOLUME 291 • NUMBER 46
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All buffers were supplemented with complete protease inhibitor (Roche Applied Science), phosphatase inhibitors (2.5 mM sodium pyrophosphate, 1 mM 2-glycerol phosphate, 1 mM sodium orthovanadate), and NFAT kinase inhibitors (2 M JNK inhibitor VII, 2 M kenpaullone, 2 M PD169-316, 10 M ellagic acid).
Protein complexes were isolated by incubation with streptavidin-agarose beads for 1 h at 4°C. Beads were washed two times with lysis buffer and four times with 20 mM HEPES, 150 mM NaCl, 0.1% IGEPAL-Ca630 (Nonidet P-40). Bound proteins were eluted either by incubation in 2ϫ reducing Laemmli buffer for 10 min at 95°C (for Western blotting analysis) or by incubation in TEV protease buffer (50 mM Tris/HCl, 5 mM citrate, 3 mM glutathione, 0.3 mM oxidized glutathione, 0.1% IGEPAL-Ca630, pH 8) containing TEV for 2 h at room temperature (for MS analysis).
For the MS experiments, the procedure followed the same protocol. Beads from corresponding pairs of heavy and light cells were mixed after the first washing step. TEV eluates were supplemented with 1/6 volume of 6 ϫ Laemmli buffer and separated on a precast gradient SDS-PAGE (Bio-Rad). Each lane was cut by hand into 16 slices, and in-gel tryptic digestion was performed as described (91) .
Quantitative Mass Spectrometry-Tryptic peptides were analyzed by a reversed-phase capillary liquid chromatography system (Ultimate 3000 nanoLC system (Thermo Scientific)) connected to an Orbitrap Elite mass spectrometer (Thermo Scientific). LC separations were performed on a capillary column (Acclaim PepMap100, C18, 3 m, 100 Å, 75 m inner diameter ϫ 25 cm, Thermo Scientific) at an eluent flow rate of 300 nl/min using a linear gradient of 3-35% B in 60 min. Mobile phase A contained 0.1% formic acid in water, and mobile phase B contained 0.1% formic acid in acetonitrile. Mass spectra were acquired in a data-dependent mode with one MS survey scan with a resolution of 60,000 (Orbitrap Elite) and MS/MS scans of the 15 most intense precursor ions in the linear trap quadrupole.
Identification and quantification of proteins were performed using MaxQuant (version 1.5.1) software. Data were searched against the Uniprot human protein database (December, 2014). The initial maximum mass deviation of the precursor ions was set at 20 ppm, and the maximum mass deviation of the fragment ions was set at 0.35 Da. Methionine oxidation and the acrylamide modification of cysteine were used as variable modifications. False discovery rates were Ͻ1% based on matches to reversed sequences in the concatenated target-decoy database. Proteins were considered if at least two sequenced peptides were identified (at least 1 unique peptide and at least 2 razor ϩ unique peptides). The criterion for quantification was a ratio count of at least 2.
Immunoblotting-Immunoblotting was performed as described (84) . Signal quantification was done by Odyssey 2.1 software (LiCOR) using adequate background subtraction. For quantitative analyses over several experiments (Figs. 3 and 6) , the signals of co-precipitated proteins were normalized to the signal of the corresponding bait proteins.
Proximity Ligation Assay (PLA)-The proximity ligation protocol was adopted from Leuchowius et al. (92) , using reagents from the Duolink starter kit (Sigma). T cells were stimulated with PMA/ionomycin or with T cell activator beads for 60 min, washed in PBS, and incubated in fixation/permeabilization buffer (eBioscience) at a concentration of 5⅐10 6 cells/ml for 2 h at 4°C. Primary human T cells were stained with live/dead stain before fixation and sorted for Pacific-Orange negative cells via FACS. The cells were incubated with primary antibodies (antiIkaros 1:1000 and anti-NFATc2 1:200) overnight at 4°C in 100 l of permeabilization (eBioscience) buffer.
The following day, PLA was performed as described (92) . For imaging, cells were spun on a glass slide, and PLA mounting medium containing DAPI was added. Image acquisition was done on a Keyence Biorevo BZ-9000 at room temperature. Images from Jurkat cells for PLA signal quantification were acquired with ϫ20 objective; all other images with ϫ100 objective using oil immersion. PLA signals were acquired in the TRITC channel and quantified using BlobFinder (93) . All parameters were adjusted to the image properties, but remained unchanged within one experiment.
The following cells were manually excluded from the statistical analysis: Jurkat cells with a nuclear size of less than 400 pixels or more than 1000 pixels, CD4
ϩ T cells with a nuclear size of less than 3500 or more than 10,000 pixels, cells that were cut by the image boarder, other cells that were incorrectly recognized by the program, as judged by visual inspection. Significance was probed using Kruskal-Wallis test.
NFAT Reporter Gene Assay-10 6 Jurkat cells were transfected by Nucleofection with 0.2 g of Renilla-TK vector (pGL3) and 2 g of either NFAT-luciferase vector (pGL3) or pGL3-control vector. The next day, cells were incubated with inhibitors for 30 min prior to stimulation for 5 h with PMA/ionomycin.
HEK293FT cells were seeded in 96-well plates in DMEM without antibiotics. The next day, cells were transfected with 22 ng of NFAT-Firefly luciferase plasmid, 22 ng of BirA-expression plasmid, 0.5 ng of Renilla-luciferase-TK plasmid, and 22 ng of target vector using Lipofectamine LTX (Invitrogen) to the manufacturer's protocol. After 5 h, cells were stimulated with PMA and ionomycin for 16 h.
Luciferase activity was measured using Dual-Luciferase reporter assay system (Promega) following the producer's manual. Measurement was done on Orion L microplate luminometer (Berthold). Firefly luciferase light units were normalized to corresponding Renilla luciferase light units, and all resulting relative light units in one experiment were normalized to the average of untreated stimulated cells.
Bioinformatic Analysis-Public ChIP-Seq data were downloaded from Gene Expression Omnibus (GEO Accession GSM157075) with corresponding controls. Bases with quality below 20 were trimmed, and only reads with existing barcodes, as defined by the original authors, were used (32) . Remaining reads were mapped against MM10 using Bowtie with parameters: -v, -best, -strata, and -C if color-coded. Mapped reads were filtered for duplicates using Picard Mark Duplicates function. Peaks were identified using MACS2 with default options for mouse genomes.
Position weight matrices of NFAT were obtained from the JASPAR, SwissRegulon, TRANSFAC, and Homer databases (94 -97) . All other motifs were obtained from the JASPAR vertebrate database. Single-Motif enrichment was performed using the web-based tool oPOSSUM (46) . GC-matched background sequences were generated using the tool available on the oPOSSUM website. In addition, the background sequences were adjusted to match the length distribution of the foreground sequences. A matrix match threshold of 85% was used in all analyses.
The localization of transcription factor-binding sites (TFBS) around putative NFAT-binding sites was determined using the oPOSSUM-anchored combination site analysis. In this type of analysis, TFBS are counted within a defined distance from the hits of the anchoring motif (the NFAT_Q4_01 motif from the TRANSFAC database in our case, as it showed the highest enrichment among all tested NFAT motifs in the single motif analysis). The localization score was calculated by subtracting the background normalized rate of hits per bp within a distance of 100 bp from the corresponding rate within a distance of 20 bp. A positive score indicates that TFBS are preferentially located close to NFAT-binding sites.
Co-enrichment was performed using the R/Bioconductor package "cobindR" (47) . This software uses hits obtained in a single motif analysis as described above and compares the occurrence of particular distances between putative TFBS of motif pairs of interest. It determines significant distances between motif pair hits by comparison with the null hypothesis of Poisson distributed distances. In addition, the distribution of distances is compared with the corresponding distribution for the control sequences. CobindR optionally takes into account the orientation of motifs and distinguishes between positive and negative distances. Motif logos were generated using the R/Bioconductor Packages Biostrings and TFBSTools (98, 99) .
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